AEON Biopharma expects $6.2 million in gross proceeds from warrant exercises
AEON•AEON Biopharma expects approximately $6.2 million in gross proceeds after certain warrant holders agreed to exercise at reduced prices. The company cut the Two-Year Warrants’ exercise price to $0.20 and the Pre-Funded Warrants’ price to $0.1999.
1. Reduced exercise prices
AEON Biopharma reduced the Two-Year Warrants’ common stock exercise price to $0.20 from $0.3221, effective November 2, 2026. The exercise price for Pre-Funded Warrants fell to $0.1999 from $0.3220.
2. Warrant terms
Certain holders agreed to exercise at the reduced prices, generating expected gross proceeds of approximately $6.2 million. The amendment applies to all outstanding Two-Year Warrants, and the underlying share counts remain unchanged. The warrants expire November 16, 2026, following an accelerated expiration triggered by the September 30, 2026, announcement of FDA meeting minutes.
